Erratum

This article refers to:

Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

Correction to: Rautenberg T, Siebert U, Arnold D, et al. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. J Med Econ 2014;17:99–110

Following publication of this article, the authors have been made aware of two errors:

Table 3 reports the Median PFS for 3L PAN as 8 months instead of 8 weeks = 2.0 months. As a result, in the section headed ‘Comparison of clinical outcomes’ the sequence with the maximum expected PFS health outcomes uses an anti-EGFR in 3L (Bev 7.5 mg + XELOX > BEV 5 mg + simplified FOLFIRI > CET 250 mg weekly + Iri) with a maximum benefit of 19.2 months. The large difference in outcomes is not driven by the favorable results of the 3L PAN studies compared to the use of BSC alone in 3L. Two (not four) of the top five sequences where health outcome are maximized include sequential bevacizumab-based regimens with an expected combined median PFS of 18.8 and 19.2 months, respectively. In Table 5 sequences with 3L regimens for PAN + BSC (last two regimens in original text) should have Median PFS 2.0 months; total sum of PFS 17.1 months. In Table 6 the second to last sequence (original text) will be listed with other sequences of sum PFS 17.1 months. The revised version is: 3L BEV 5 mg + FOLFOX 4 (NO16966)1 (9.4 months) €42,233; BEV 5 mg + simplified FOLFIRI (ML 18147) (5.7 months) €29,129; PAN + BSC2 (KOL regimen PAN alone) (2.0 months) €10,013; SUM PFS 17.1 months Total Sequence Cost = €81,375, Average Monthly Cost = €4758. The last sequence will be listed with other sequences of sum PFS 17.1 months. The revised version is: 3L BEV 7.5 mg + XELOX (NO169661; p.2) (9.4 months) €43,694; BEV 5 mg + simplified FOLFIRI (ML 18147) (5.7 months) €29,129; PAN + BSC2 (KOL regimen PAN alone) (2.0 months) €10,013; SUM PFS 17.1 months. Total Sequence Cost = €82,836; Average Monthly Cost = €4844.

In Table 1, for Cetuximab the EMR6 22 02-007 (BOND) study has been erroneously linked to the Pfeiffer3,4 publications where the reported Median PFS is 5.4 months. The correct link is Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-455, which demonstrated a Median PFS of 4.1 months for Cetuximab+Irinotecan. In Table 5: 3L regimen cet 250 mg weekly+Iri should be referenced as Cunningham 20045 with Median PFS 4.1 months; sum of PFS 19.2 months. Therefore in Table 3 the Median PFS of 3L regimen CET 250 mg weekly + iri should be 4.1 months. In Table 6 the third from last sequence (original text version) should read 3L BEV 7.5 mg + XELOX (NO169661; p.2) (9.4 months) €43,694; BEV 5 mg + simplified FOLFIRI (ML 18147) (5.7 months) €29,129; CET 250 mg weekly + Iri5 (4.1 months) €27,242; SUM PFS 19.2 months. Total Sequence Cost = €100,065, Average Monthly Cost = €5211 and becomes listed as the last sequence. The reference Cunningham 20045 replaces Pfeiffer 20084 for cet250 mg weekly+Iri in Tables 4 and 7.

The results and conclusions of the study are based on standardized PFS for all sequences and are therefore not affected by these changes.